Cyclopharm Limited · ASX:CYC
Cyclopharm — Shareholder Meeting (May 2009)
25 slides from Cyclopharm's shareholder meeting presentation, May 21, 2009
Slide 1: Cyclopharm Limited Annual General Meeting 21 May 2009
For personal use only Cyclopharm Limited Annual General Meetingg 21 May 2009
Slide 2: Disclaimer
Disclaimer For personal use only Certain views expressed here contain information derived from publicly available sources that have not been independently verified. The presentation includes certain statements, estimates and projections with respect to the anticipated future financial performance of
Slide 3: Agenda
Agenda g For personal use only Chairman’s Address Managing Director’s Review Question Time Business Close 3
Slide 4: Chairman's Address
For personal use only Chairman’s Address Vanda Gould 4
Slide 5: Managing Director's Review
For personal use only Managing Director’s Review James McBrayer 5
Slide 6: Cyclopharm business
Cyclopharm business Two main business units For personal use only Technegas Molecular Imaging Established in 1986 continues to Establishment of PET central generate revenue, profits and pharmacies to produce PET strong cash flows through the radiopharmaceuticals for Australia manufacture and distrib
Slide 7: Highlights - Financial Year 2008
Highlights ‐ Financial Year 2008 For personal use only 9 Profits up 55% and EPS up 49% 9 Net cash flow up $3.0 million 9 Equity and financing secured for growth 9 FDA progressing 9 New Technegas applications in the pipeline 9 PET Nuclear pharmacy plan on track 9 Government funding approvals for PET
Slide 8: Technegas
Technegas g For personal use only There are three components required Components of Technegas f a Technegas for T h procedure: d 1. Technegas Generator 2. A single use Patient Administration Set 1. Generator (PAS) 3. A single use patient crucible 2. PAS Technegas Generators Generators, PAS component
Slide 9: Technegas Global footprint
Technegas Global footprint For personal use only • Technegas is sold in 55 countries across the world • Over 2,160,000 patient studies since 1986 • 160,000 patient studies conducted in 2008 • 1,100 Technegas generators sold globally Asia • Patents in 36 countries Europe, Pacific 15% Middle Americas
Slide 10: Molecular Imaging - Positron Emission Tomography (PET)
Molecular Imaging ‐ Positron Emission Tomography (PET) For personal use only PET is the future of Nuclear Medicine. Positron Emission Tomography allows physicians to diff differentiate i between b healthy h l h andd active i diseased di d tissue and therein: •Detect Detect cancer and other disease s
Slide 11: Molecular Imaging Industry Developments
Molecular Imaging Industry Developments For personal use only Improved Technology PET is the future of Nuclear medicine. As a result, equipment manufacturers are investing heavily in the advancement and development of improved and integrated technologies. Additional Government Funding Approved Austr
Slide 12: 2008 Financials
For personal use only 2008 Fi Financials i l 12
Slide 13: Profit & Loss
Profit & Loss For personal use only 9Net profit after tax increases 55% • Technegas related sales revenue was compared to the prior period. 2008 2007 $ $ • Gross profit margins and profitability CONTINUING OPERATIONS improved due to a shift in sales mix Total revenue 10,937,646 11,229,630 Expenses (
Slide 14: Sales revenue - Segmental Review
Sales revenue ‐ Segmental Review For personal use only 9 Consolidated profit margins improve Patient Administration Sets (PAS) • Targeting T ti margin i improvement i t in i 2008 • PAS revenue up 11.9% to $9.3 m • PAS volumes down 5% TechnegasPlus • 2007 200 iintroductory d offer ff not extended d d
Slide 15: Sales revenue Half year comparison
Sales revenue Half year comparison For personal use only 9 Historical Trend – strong second half results continue 15
Slide 16: Strong Balance Sheet
Strong Balance Sheet For personal use only 9 Funding secured for strategic growth • $3.18m raised through fully subscribed rights issue (before Balance Sheet Summary 2008 2007 issue costs off $0.15m) $ ) $ $ • Debt facility increased to $6.45m Total Current Assets 12,443,583 7,763,729 Total Non-curr
Slide 17: Robust Operating Cash flow
Robust Operating Cash flow For personal use only 9 Net cash flow increases $3.0m over prior year • The improvement in operating cash flows resulted from reduced expenses 2008 2007 and favourable currency movements $ $ Net cash flows from • Higher inventory balance driven by operating activities 1,48
Slide 18: Business Objectives 2009
For personal use only Business Objectives 2009 18
Slide 19: Business Overview 2009 - Technegas
Business Overview 2009 Technegas For personal use only New Drug Application (NDA) • NDA submitted December 2008 • Application withdrawn February 2009 based on initial FDA feedback • Once filed filed, approval is expected within 12 months New Indications for Technegas • Currently in discussions with
Slide 20: Business Overview 2009 - Molecular Imaging
Business Overview 2009 Molecular Imaging For personal use only Macquarie University Private Hospital (MUPH) • Cyclotron ordered, bunker constructed and fit out commencing June 2009 • Sales forecasted for 2010 Melbourne • Construction scheduled to follow regulatory approval of MUPH Government Funding
Slide 21: Conclusion
For personal use only C l i Conclusion 21
Slide 22: Highlights - Financial Year 2008
Highlights ‐ Financial Year 2008 For personal use only 9 Profits up 55% and EPS up 49% 9 Net cash flow up $3.0 million 9 Equity and financing secured for growth 9 FDA progressing 9 New Technegas applications in the pipeline 9 PET Nuclear pharmacy plan on track 9 Government funding approvals for PET
Slide 23: Question Time & Business
For personal use only Q ti Ti Question Time & B Business i 23
Slide 24: Proxy Summary
Proxy Summary For personal use only Resolution Business For* Against Abstain Proxy’s di discretion ti 1 Remuneration Report 111,459,346 202,791 9,327 350,100 2 Re-election of Mr David 111,615,635 55,829 - 350,100 James Heaney 3 Election of Mr John Stuart 108,972,952 55,829 2,642,683 350,100 Sharman
Slide 25: Attachments
For personal use only Att h t Attachments 25